Gadopentetate Dimeglumine

钆喷酸葡胺

Report date: 2022/08/16 20:00:19
NME

Base Information

Drug NameGadopentetate Dimeglumine
Drug Alias Name磁显葡胺Meglumine Gadopentetate二乙烯三胺五醋酸钆双葡甲胺钆喷酸二甲葡胺钆喷酸葡甲胺 +[11] 
ClassificationSmall moleculesDiagnostic agent (In vivo) > Contrast agent
Mechanisms of ActionMagnetic resonance imaging enhancers
TargetsNot applicable
Therapy Area/IndicationsPlaque psoriasisContrast agentsSolid tumours +[26] 
Global Approved IndicationsContrast agents
Approved Indications in ChinaContrast agents
Original Approved Country/TerritoryUnited States
Original Approved Date1988/06/02
Country/TerritoryUnited StatesArgentinaMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Consun Pharmaceutical Co Ltd
Inactive CompaniesAsis CorporationNational Institutes Of Health Clinical Center (Cc)Masonic Cancer Center, University Of Minnesota +[7] 
Active IndicationsContrast agents
Inactive IndicationsPlaque psoriasisSolid tumoursConstriction, Pathologic +[25] 

Other Information

ATC CodeV08CA01
Related LinksWikipediaDrugBankKEGG